Pharmacom Net Tangible Assets from 2010 to 2026
| PHMB Stock | USD 0.0001 0.00 0.000003% |
Net Tangible Assets | First Reported 2010-12-31 | Previous Quarter 53.3 K | Current Value 55.9 K | Quarterly Volatility 12.1 K |
Check Pharmacom Biovet financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharmacom Biovet's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 475.5 K or Total Revenue of 0.0, as well as many indicators such as . Pharmacom financial statements analysis is a perfect complement when working with Pharmacom Biovet Valuation or Volatility modules.
Pharmacom | Net Tangible Assets | Build AI portfolio with Pharmacom Stock |
Analyzing Pharmacom Biovet's Net Tangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Tangible Assets has evolved provides context for assessing Pharmacom Biovet's current valuation and future prospects.
Latest Pharmacom Biovet's Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Pharmacom Biovet over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Pharmacom Biovet's Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharmacom Biovet's overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Pharmacom Net Tangible Assets Regression Statistics
| Arithmetic Mean | 44,511 | |
| Coefficient Of Variation | 27.12 | |
| Mean Deviation | 5,363 | |
| Median | 46,325 | |
| Standard Deviation | 12,071 | |
| Sample Variance | 145.7M | |
| Range | 57K | |
| R-Value | 0.52 | |
| Mean Square Error | 113.8M | |
| R-Squared | 0.27 | |
| Significance | 0.03 | |
| Slope | 1,237 | |
| Total Sum of Squares | 2.3B |
Pharmacom Net Tangible Assets History
About Pharmacom Biovet Financial Statements
Pharmacom Biovet stakeholders use historical fundamental indicators, such as Pharmacom Biovet's Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Pharmacom Biovet investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pharmacom Biovet's assets and liabilities are reflected in the revenues and expenses on Pharmacom Biovet's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pharmacom Biovet. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 53.3 K | 55.9 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pharmacom Biovet offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pharmacom Biovet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmacom Biovet Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmacom Biovet Stock:Check out the analysis of Pharmacom Biovet Correlation against competitors. For information on how to trade Pharmacom Stock refer to our How to Trade Pharmacom Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharmacom Biovet. Anticipated expansion of Pharmacom directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pharmacom Biovet assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Pharmacom Biovet's market price often diverges from its book value, the accounting figure shown on Pharmacom's balance sheet. Smart investors calculate Pharmacom Biovet's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Pharmacom Biovet's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Pharmacom Biovet's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pharmacom Biovet should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Pharmacom Biovet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.